DxMedical Cloud™
Technology for overwhelmingly high-speed detection from all over the world.
We use our unique algorithm to deliver the latest technology and product information
from around the world in real time.
Explore the future of healthcare with carefully selected information.
Explore the future of healthcare with carefully selected information.
How We Help You To Empower Your Business
POINT 1.
Quickly Deliver Technical Information
We deliver what you seek quickly and in a short time from technical information
from all over the world
POINT 2.
Briefly to the Point
A wealth of detailed features makes it easy to understand the main points
POINT 3.
Help with Growth Strategies
The report is also packed with analytical information from the perspective of
growth and long-term strategies for business use
Catch Up on the Latest Information
from Around the World
from Around the World
In today's world, where the world is networked by advances in information technology and
numerous technologies are evolving at an astonishing speed, it is extremely difficult to
manually collect and manage the vast amount of information from all over the world.
DxMedical Cloud™ collects and analyzes professional information from around the
world and uses proprietary algorithms to quickly and accurately deliver the information
you seek and the best information for you.
search
Quick search in Japanese
You can quickly search for information published in various languages around the
world in Japanese. Get the information you need from the vast amount of information
available worldwide without having to worry about language barriers.
emergency
Recommendations for You
DxMedical Cloud's proprietary algorithms predict the best information based on your
interests and preferences and deliver it to you daily. Stay one step ahead of the
curve without the hassle of searching, maximizing your daily information gathering.
Fuzzy Search
In addition to word matching, the search by similar and related keywords delivers
news that is often missed due to paraphrasing and shaky spelling.
Japanese Localization
By providing titles and summaries of information from around the world in Japanese,
it streamlines the process of “finding” the information you want from search
results.
Academic Search
For researchers and professionals, you can search and browse more specialized
information, such as articles submitted to journals by universities and research
institutes.
More features to enhance your team's productivity
Bookmark
Instantly save and manage information that you like or want to look at later because
you don't have time, with the bookmark function. You can access the information you
need without hassle, saving you a great deal of time and effort.
Note Editor
Simple and intuitive operation allows you to quickly consolidate all information
into a notebook and organize information efficiently. It can be used as a powerful
tool for effective information sharing.
Information sharing
A wide range of information sharing tools are available, including chat and note
sharing functions. We support information sharing with your team in all situations,
from casual information sharing to organizing information in teams.
Collaboration
Provides task management functions specifically designed to make information
gathering and sharing more efficient. In addition to regular task management
functions, this useful tool supports information gathering and sharing, improving
the productivity of the entire team.
DigitalMedical Open Innovation
BrainEnergy produce DigitalMedical
open innovation from Tokyo, where you can experience the intersection of cool and passionate
design and technology.
Transform Your Business With Cloud
Looking for the Future of Health Care
OUR TECHNOLOGY HELPS YOUR BUSINESS
Our technology will help your business
Technology
“Does Buckwheat Starch Affect Cognitive Function?” Japanese Flour Milling Company Reports on Potential Mechanism Involving Gut Bacteria Through Industry-Academia Collaboration
Nikko Seifun has revealed the results of a joint study with Shinshu University on the potential for buckwheat-derived starch to influence cognitive function via the gut microbiota. The study was presented at the 2025 Sapporo Conference of the Japanese Society for Agricultural Chemistry. The research began in 2020 as part of an industry-academia collaboration involving Nagano Prefecture, Shinshu University, and the company. In partnership with the Food Chemistry Laboratory at Shinshu University (led by Professor Shigeru Katayama), the company provided buckwheat flour samples to initiate the study, with the aim of exploring the health benefits of buckwheat and fermented foods—both local resources. Initial investigations evaluated the potential anti-aging properties of buckwheat. Subsequently, full-scale functional research has been conducted as a joint project. The composition of buckwheat flour varies depending on the part of the grain from which it is milled; it is broadly categorized into inner-layer flour, which is rich in starch, and outer-layer flour, which is rich in dietary fiber. The research focused primarily on buckwheat starch and conducted verification using mice with an accelerated aging model. The results showed that in the group that consumed buckwheat starch, improvements in cognitive function were observed alongside changes in the gut microbiota. On the other hand, under conditions where the gut microbiota was eliminated using antibiotics, this effect disappeared, suggesting that gut bacteria may be involved in the mechanism. While dietary fiber and resistant starch are generally considered to be involved in improving the intestinal environment (Note 1), the buckwheat starch used in this study contains almost none of these components. This suggests that the structure of the starch itself may be influencing gut bacteria, and analysis of active ingredients and structural characteristics is currently underway. The company plans to continue its research with an eye toward the potential for this starch to be used as an ingredient in foods with functional claims. A representative from the research and development department explained, “Since starch is generally treated as an energy source, there are many challenges to having it recognized as a functional ingredient. However, we aim to elucidate the active components and mechanisms in the near future and achieve practical application.” Furthermore, they added, “If its functionality is established, we are also considering its development as a commercial ingredient for noodle manufacturers and others.” As findings demonstrating new functionalities of grain-derived starch emerge, attention is likely to focus on its potential applications as a food ingredient. (Note 1: While it cannot be generalized due to differences in measurement methods and samples, buckwheat is generally considered to contain a high amount of resistant starch.)
.
.
.
.
A Tiny Sensor That Reads Creatinine in Seconds
EurekAlert (March 31, 2026) reported on a compact chemiresistive biosensor developed by Tohoku University (in collaboration with the City College of New York), published in Microsystems & Nanoengineering, that measures creatinine in approximately 35 seconds. Creatinine is a key marker of kidney function, but conventional measurement methods require bulky instruments or suffer from interference. Sensor features: A chemiresistive biosensor with platinum nanoparticle-polymer composite functionalized with three enzymes (creatinine deiminase and enzyme cascade). Two-electrode configuration eliminating the need for a reference electrode: Achieves system miniaturization, simplification, and cost reduction by eliminating the reference electrode required in conventional electrochemical biosensors. Operating principle: Hydrogen peroxide (H2O2) generated by enzyme reactions alters charge transport within the nanoparticle network, detected as electrical resistance changes. 10-µm electrode gap, detection range covers clinically relevant urinary creatinine concentrations (1–300 mg/dL). Nanoparticle network designed near the percolation threshold significantly amplifies small redox changes. Future outlook: Real-world validation in urine and blood samples, adaptation to other biomarkers (possible with recognition chemistry modification alone), and application to portable home diagnostic devices and creatinine normalization of urinary biomarkers are anticipated.
.
.
.
.
Flexible Sensors Tested in Bedsheets to Lessen Patient Ulcers
Fierce Sensors (March 18, 2026) reported on a sheet-type flexible sensor system developed jointly by Georgia Tech and Children's Healthcare of Atlanta to prevent pressure injuries (PIs). PIs affect 2.5 million patients and cause 60,000 deaths annually in the US, with $27 billion spent on medical care each year. Current prevention relies on manually turning bedridden patients every few hours, hampered by uncertainty about when and how quickly PIs form. The sensor system weaves pressure and moisture sensors into a bedsheet-like fabric to collect real-time data from patients lying in bed or sitting in wheelchairs. Machine learning and predictive analytics are used to predict PI risk and formation timing, alerting nurses to reposition patients at the right moment. The system adapts to each patient's weight and condition, customizing responses based on sustained pressure and moisture levels. Georgia Tech Professor Sundaresan Jayaraman and principal research scientist Sungmee Park have collaborated since 2017, evolving from prototypes requiring dozens of cables to a streamlined single-cable-per-bed system. The design also achieves non-intrusiveness with fragile premature infants and washability. Currently being piloted in a pediatric intensive care unit (PICU), the goal is deployment across 50 beds, with future integration into electronic medical records and commercialization for widespread healthcare adoption.
.
.
.
.
Personal Care Microbiome Testing Startup Raises $3.5M to Deliver Actionable Insights Enhancing Product Efficacy and Consumer Trust
Raising.fi (March 17, 2026) reported that Sequential, a Cambridge, England-based startup specializing in advanced microbiome testing for personal care products, successfully raised $3.5 million in its latest funding round. The round was led by a notable food biotech investor, with participation from Corundum Systems Biology, Dermazone Holdings, SOSV, Scrum Ventures, and Innovate UK. Co-founded by a Chief Scientific Officer and a Chief Executive Officer, the company aims to deliver actionable insights that help personal care brands improve product performance and build consumer trust. By leveraging advanced microbiome testing methods, Sequential enables brands to optimize their formulations based on scientific data. The newly acquired funds are expected to advance the company's microbiome testing capabilities, potentially expanding product offerings, enhancing research capabilities, and broadening market presence in the personal care sector.
.
.
.
.
Agricultural Waste-Derived Biochar Enables pH-Responsive Targeted Intestinal Delivery of Natural Antimicrobial Enzyme as Antibiotic Alternative in Livestock Feed
EurekAlert! (March 17, 2026; published in Biochar, DOI: 10.1007/s42773-025-00557-w) reported on a study showing that biochar derived from agricultural waste—specifically chestnut shells and vine pruning residues—can serve as a carrier for lysozyme, a natural antimicrobial enzyme found in egg whites, enabling pH-responsive targeted delivery in the intestine. Antimicrobial resistance (AMR) is a growing global concern partly driven by antibiotic overuse in livestock farming, particularly during vulnerable stages such as weaning. While lysozyme is a promising antibiotic alternative as a functional feed additive, its effectiveness is limited because it degrades in the acidic gastric environment. The research team used a mild, water-based process to attach lysozyme onto two types of biochar and conducted release experiments under conditions mimicking the digestive tract of young pigs. At low pH (simulating the stomach), only a very small amount of lysozyme was released, maintaining stability; at neutral pH (simulating the intestine), release increased significantly, confirming targeted intestinal delivery. Advanced imaging and spectroscopy confirmed uniform distribution of lysozyme across the biochar surface—rather than aggregation—which likely contributes to stability and controlled release. The approach also highlights the value of agricultural waste valorization: materials typically burned or discarded can be converted into high-value products that support sustainable farming, reduce greenhouse gas emissions, and improve nutrient management. The researchers note that similar strategies could be explored in human nutrition and pharmaceutical delivery.
.
.
.
.
“Does Buckwheat Starch Affect Cognitive Function?” Japanese Flour Milling Company Reports on Potential Mechanism Involving Gut Bacteria Through Industry-Academia Collaboration
Nikko Seifun has revealed the results of a joint study with Shinshu University on the potential for buckwheat-derived starch to influence cognitive function via the gut microbiota. The study was presented at the 2025 Sapporo Conference of the Japanese Society for Agricultural Chemistry. The research began in 2020 as part of an industry-academia collaboration involving Nagano Prefecture, Shinshu University, and the company. In partnership with the Food Chemistry Laboratory at Shinshu University (led by Professor Shigeru Katayama), the company provided buckwheat flour samples to initiate the study, with the aim of exploring the health benefits of buckwheat and fermented foods—both local resources. Initial investigations evaluated the potential anti-aging properties of buckwheat. Subsequently, full-scale functional research has been conducted as a joint project. The composition of buckwheat flour varies depending on the part of the grain from which it is milled; it is broadly categorized into inner-layer flour, which is rich in starch, and outer-layer flour, which is rich in dietary fiber. The research focused primarily on buckwheat starch and conducted verification using mice with an accelerated aging model. The results showed that in the group that consumed buckwheat starch, improvements in cognitive function were observed alongside changes in the gut microbiota. On the other hand, under conditions where the gut microbiota was eliminated using antibiotics, this effect disappeared, suggesting that gut bacteria may be involved in the mechanism. While dietary fiber and resistant starch are generally considered to be involved in improving the intestinal environment (Note 1), the buckwheat starch used in this study contains almost none of these components. This suggests that the structure of the starch itself may be influencing gut bacteria, and analysis of active ingredients and structural characteristics is currently underway. The company plans to continue its research with an eye toward the potential for this starch to be used as an ingredient in foods with functional claims. A representative from the research and development department explained, “Since starch is generally treated as an energy source, there are many challenges to having it recognized as a functional ingredient. However, we aim to elucidate the active components and mechanisms in the near future and achieve practical application.” Furthermore, they added, “If its functionality is established, we are also considering its development as a commercial ingredient for noodle manufacturers and others.” As findings demonstrating new functionalities of grain-derived starch emerge, attention is likely to focus on its potential applications as a food ingredient. (Note 1: While it cannot be generalized due to differences in measurement methods and samples, buckwheat is generally considered to contain a high amount of resistant starch.)
.
.
.
.
A 3D renal cell model developed based on dialysis research: Expected to be applied to the evaluation of nephrotoxicity in drug development
Nikkiso has developed “3D-RPTEC®,” a cell model for drug discovery research that involves the three-dimensional culture of human renal proximal tubule epithelial cells (RPTEC). This technology is expected to serve as a new evaluation system in pharmaceutical research, functioning as a human-derived renal cell model that can be utilized for assessments such as nephrotoxicity evaluation. Sales of the product began in 2023. The company’s research into this technology was driven by the artificial kidney technology it has cultivated through its hemodialysis business. Conventional artificial kidneys rely on filters to separate substances based on molecular size, but they cannot replicate physiological functions such as reabsorption, which are inherent to the kidney. Consequently, the company has been advancing research on a “hybrid bio-artificial kidney” that incorporates cellular functions, and as part of this effort, has been developing culture techniques to enhance the functional expression of renal epithelial cells. During the research process, it was confirmed that culturing cells as spheroids (spherical aggregates) could elicit the intrinsic functions of renal cells, and these findings were subsequently applied to drug discovery research. In the field of drug discovery, pharmacokinetic and safety evaluations have traditionally relied heavily on animal testing; however, limitations in predictive accuracy due to physiological differences between animals and humans, as well as the significant burden of such experiments, have posed challenges. As an evaluation system using human cells, 3D-RPTEC® is characterized by its ability to detect nephrotoxicity originating from the proximal tubules. While its use is currently envisioned primarily for toxicity evaluation, applications in pharmacokinetics and pharmacology are also being considered. Moving forward, the company plans to leverage technology that allows for cryopreservation of the spheroids in their intact state to expand into the European and American markets. Furthermore, the company is working to establish guidelines for nephrotoxicity assessment using this technology, aiming to establish an evaluation system that becomes a global standard. A representative from the company’s Bio Business Promotion Department stated, “We do not intend to handle cell products solely on our own; rather, we aim to advance research and development and commercialization in collaboration with various companies and research institutions. We will actively pursue such collaborations.” They further explained, “While single-cell freezing technology is widely used, there are few examples where freezing technology for spheroids has been established to a commercial level, and this is one of our strengths.” Going forward, the company intends to expand the scope of application for this technology through the advancement of freezing techniques and collaboration with other institutions, aiming to establish an evaluation system that will become the new standard for nephrotoxicity assessment in drug discovery research.
.
.
.
.
New technology could use sunlight to break down 'forever chemicals'
An international research team led by Professor Frank Marken at the University of Bath, in collaboration with scientists from the University of São Paulo, the University of Edinburgh, and Swansea University, has developed a prototype photocatalyst capable of using sunlight to break down polyfluoroalkyl substances (PFAS)—a class of highly stable, water-repellent chemicals widely used in products including non-stick cookware, cosmetics, waterproof clothing, and fire-extinguishing foam. The findings were published in the journal RSC Advances. Because PFAS do not degrade naturally, they accumulate in the human body, water systems, food chains, and the wider environment, and some studies have linked them to an increased risk of cancer. The newly developed catalyst combines carbon nitrite with a rigid microporous polymer: the polymer binds PFAS molecules to the catalyst surface, which then uses light energy to break them down into carbon dioxide and fluoride—a substance found in toothpastes. Professor Marken noted that current PFAS detection requires expensive, specialist laboratory equipment, and expressed hope that the technology could eventually underpin simple portable sensors for field use, enabling detection of elevated PFAS concentrations in the environment. The team aims to scale up and further optimize the technology for potential environmental remediation applications.
.
.
.
.
UK Care Provider Partners with University to Develop Nutrient-Rich 3D Printed Food for Elderly Residents with Dysphagia
VoxelMatters (March 12, 2026, by Joseph Caron-Dawe) reported that Spellman Care, a company operating nursing homes for elderly residents in Yorkshire, UK, has partnered with the University of Leeds to explore the use of 3D printed food to improve nutrition and dining experiences for elderly residents with dysphagia—a swallowing condition requiring texture-modified diets. Traditional texture-modified foods such as mashes and purees reduce choking risk but suffer from poor visual appeal and reduced nutritional density due to water addition; malnutrition is a major issue affecting 50% of people in care homes. Dr. Steffen Hirth, Research Fellow in Sustainable and Resilient Food Systems at the University of Leeds, noted that approximately 1.3 million adults aged 65+ in the UK are at risk of malnutrition due to swallowing difficulties. The collaboration began with semi-structured interviews at each of Spellman Care's homes, pairing head chefs with nursing and care professionals to gather practical feedback on kitchen operations and potential integration of 3D printing technology. The goal is to develop 3D printed foods that are safe, nutritious, and enjoyable for residents. The next phase will see Spellman Care representatives travel to the University of Leeds to trial 3D printed food prototypes firsthand. Philippa Young, Operations Manager at Spellman Care, stated that the company's early involvement is intended to ensure outcomes are specifically tailored to the unique needs of the care industry.
.
.
.
.
New Functional Sugar Ingredients Expanding in the Oral Care Market: A New Approach to Suppressing Plaque Formation
Wellneo Sugar is advancing the development of “CI-Dextran mix,” a functional material for oral care. This material is an oligosaccharide (CI: cyclodextran) formed by glucose molecules linked in a ring structure. Its unique molecular structure inhibits the formation of dental plaque, a cause of tooth decay and periodontal disease.
Plaque forms when cavity-causing bacteria and periodontal disease bacteria synthesize insoluble glucans using sugar as a substrate. CI-Dextran mix is characterized by its ability to create an environment where plaque itself is less likely to form by inhibiting the activity of the enzyme (GTF) these bacteria utilize. This mechanism creates an environment where bacteria cannot utilize sugar, rather than simply killing them, and its effectiveness has been confirmed even in the presence of sugar. Its efficacy has already been demonstrated in clinical trials and other studies.
Cyclodextran was discovered in 1993 as a high-functionality oligosaccharide derived from microorganisms, but mass production proved difficult, delaying its practical application for a long time. Wellnessugar acquired the rights to this technology about 10 years ago and has been advancing the establishment of mass production technology through the development of its own manufacturing process.
Its key feature is maintaining functionality even when combined with sugar. It is expected to be applied in confectionery and beverages that balance functionality and taste, with inquiries already increasing from European and Asian markets.
Mr. Hikaru Kato, responsible for development, states, “Following the first generation focused on sterilization and the second generation targeting metabolic inhibition, this material represents the ‘third generation’ of oral care ingredients by suppressing plaque formation itself. Its strengths lie in being naturally derived, low-irritation, yet possessing high functionality.” As a functional ingredient originating from a sugar manufacturer, whether CI-Dextran mix will lead to the creation of new markets spanning oral care and food sectors is a development to watch.
.
.
.
.
InnoJin Initiates Partnership with Online Pharmacies to Connect Online Consultations to Post-Consultation Medication Guidance
InnoJin Inc. has launched a partnership with online pharmacies through its ophthalmology online consultation platform. This initiative aims to streamline the process of receiving prescription medications and starting treatment after online consultations, creating an environment where patients can smoothly continue their care. It enables a seamless medical experience from online consultation to medication for those with limited access to clinics or busy schedules, thereby promoting medical DX and contributing to a society where everyone can access necessary medical care. This partnership has already been implemented at "Tenohira Ophthalmology" in Bunkyo-ku, Tokyo, with phased expansion planned.
.
.
.
.
Elucidating abnormalities in gut microbiota and sex differences in Japanese adult bronchial asthma patients
Symbiosis Solutions, in a joint research with the Department of Respiratory Medicine at Nihon University School of Medicine, discovered abnormalities (dysbiosis) in the gut microbiota of Japanese adult bronchial asthma patients, with sex differences observed in the types of associated bacteria. While previous studies have reported a link between childhood asthma and gut microbiota, this connection in adult asthma was previously unclear. This study revealed an abnormal gut microbiota composition in adult asthma patients, characterized by a higher abundance of respiratory disease-related bacterial groups and fewer short-chain fatty acid-producing bacteria, also demonstrating sex-specific differences in these abnormalities. These findings suggest that gut microbiota could be a new target for the prevention and improvement of adult bronchial asthma, emphasizing the importance of considering sex differences in future approaches. The research was published in the international academic journal 'Biomedicines'.
.
.
.
.
Lactic acid bacteria that act on the immune system's starting point may suppress upper respiratory tract infections Confirmed in human trials using dairy products
Yakult Honsha Co., Ltd. conducted a clinical trial to verify the effects of consuming dairy products containing the lactic acid bacterium Lacticaseibacillus paracasei strain Shirota (L. paracasei Shirota strain, hereinafter referred to as the Shirota strain) on the onset of upper respiratory tract infections and the activity of immune cells. Previously, Shirota strain has been reported to enhance immune function by maintaining and restoring NK cell activity and maintaining salivary IgA. However, sufficient human data regarding its effects on key immune cells, which are important for inducing these actions, had not been obtained.
This trial was a randomized, double-blind, parallel-group comparative study involving 200 healthy office workers. Participants were divided into a group consuming dairy products containing 40 billion Shirota strain bacteria and a control group consuming dairy products without the bacteria. Participants consumed one bottle per day for 28 days. Results showed a significantly lower incidence of upper respiratory tract infection symptoms in the group consuming the Shirota strain-containing dairy product. The difference became particularly pronounced after two weeks of consumption, with suppression observed not only for nasopharyngeal symptoms like runny nose and nasal congestion but also for systemic symptoms such as fever and fatigue.
Blood analysis confirmed that phagocytic cells, such as conventional dendritic cells and monocytes responsible for the initial phase of the immune response, maintained high expression of activation molecules like HLA-DR and CD86. These cells are known to lead to the activation of NK cells, T cells, and B cells. This suggests that Shirota strain may act on immune cells at the starting point of the immune response, enhancing the body's defense function against upper respiratory tract infections.
Mr. Naito of the company's Fundamental Research Laboratory, who led the study, stated, “Upper respiratory tract infections, represented by the common cold and influenza, are the most common diseases, causing significant social and economic losses, making prevention critically important.” The company, grounded in the principles of preventive medicine, intends to continue deepening its immunological research aligned with people's diverse lifestyles.
.
.
.
.